<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945954</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH_MIDD_PTCy</org_study_id>
    <nct_id>NCT04945954</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Post-transplant Cyclophosphamide in Pediatric Patients</brief_title>
  <official_title>Pharmacokinetic Study of Post-transplant Cyclophosphamide in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Food and Drug Safety Evaluation (Republic of Korea)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated clinical trial to analysis population pharmacokinetic&#xD;
      characteristics and investigate appropriate pediatric dose of Cyclophosphamide in pediatric&#xD;
      hematopoietic stem cell transplantation patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameter of melphalan</measure>
    <time_frame>Day -3: post 2 hour, post 3 hour, post 6 hour, post 24 hour / Day -2: post 2 hour, post 3 hour, post 6 hour( Day 0 means the day when patients receive a HSCT)</time_frame>
    <description>Analysis: Maximum plasma drug concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameter of melphalan</measure>
    <time_frame>Day +3: post 2 hour, post 3 hour, post 6 hour, post 24 hour / Day +4: post 2 hour, post 3 hour, post 6 hour ( Day 0 means the day when patients receive a HSCT)</time_frame>
    <description>Analysis: Maximum plasma drug concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameter of melphalan</measure>
    <time_frame>D-3 post 2 hour, post 3 hour, post 6 hour, post 24 hour / D-2 post 2 hour, post 3 hour, post 6 hour / D+3 post 2 hour, post 3 hour, post 6 hour, post 24 hour / D+4 post 2 hour, post 3 hour, post 6 hour( D0 means The day when patients receive a HSCT)</time_frame>
    <description>Analysis: Area under the plasma concentration-time curve (AUC)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Drug: Cyclophosphamide</intervention_name>
    <description>Administer 14.5mg/kg of Cyclophosphamide once a day for 4days. (intravenously)&#xD;
Blood sampling of pharmacokinetics(PK) of cyclophosphamide will be performed in all patients who have taken the investigational drug for at least 4 days (For 2 days, It will be administered for pretreatment of transplant, for the other 2 days, It will be administered for Post-transplant treatment for the prevention of GVHD)</description>
    <arm_group_label>Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who had cyclophosphamide treatment for immunosuppressant after allogeneic&#xD;
             hematopoietic stem cell transplantation&#xD;
&#xD;
          -  Patients age &lt;19 years&#xD;
&#xD;
          -  Written Study Informed consent and/or assent from the patient, parent, or guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to mycophenolate mofetil or similar class of drug substance&#xD;
&#xD;
          -  Patients in a medically critical condition such as severe infection or unstable vital&#xD;
             signs&#xD;
&#xD;
          -  Any condition that would, in the Investigator's judgment, interfere with full&#xD;
             participation in the study&#xD;
&#xD;
          -  Subjects who are pregnant or breast-feeding&#xD;
&#xD;
          -  Subjects with psychiatric conditions that may interfere with the study&#xD;
&#xD;
          -  Subjects who have a possibility of the disease getting worse as a treatment for&#xD;
             clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jin Kang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>l</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hyoung Jin Kan, MD,PhD</last_name>
    <phone>+82-2-2072-3304</phone>
    <email>kanghj@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyung Taek Hong, MD,PhD</last_name>
    <phone>+82-2-2072-3631</phone>
    <email>hongkt@snu.ac.kr</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hyoung Jin Kang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

